Polarean Imaging PLC New System Delivery and Installation (9061X)
24 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 9061X
Polarean Imaging PLC
24 December 2019
Polarean Imaging Plc
("Polarean" or the "Company")
New System Delivery and Installation
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary drug-device combination product for the
magnetic resonance imaging (MRI) market, announces that the Company
has delivered and installed its latest research unit order for a
9820 Xenon Polariser system from the University of Iowa Hospitals
and Clinics ("UI Hospitals & Clinics").
The University of Iowa Hospitals and Clinics is Iowa's only
comprehensive academic medical centre; an 811-bed hospital that
annually admits about 37,000 patients for in-patient hospital care.
For more information: https://uihc.org/basic-facts
The total number of the Company's polarisers that are either
installed or on order remains 25.
Richard Hullihen, CEO of Polarean, said: "I am delighted that we
have delivered and installed another polariser, to be used by
pulmonology researchers at this well-regarded teaching hospital.
The University of Iowa has a long history in medical imaging
research and we are excited at the prospect of beginning a new
chapter in hyperpolarized xenon cardiopulmonary imaging with
them."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
David Hignell, Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimise the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCDDBDDBUDBGCX
(END) Dow Jones Newswires
December 24, 2019 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024